Autoencoder Based Feature Selection Method for Classification of Anticancer Drug Response

Anticancer drug responses can be varied for individual patients. This difference is mainly caused by genetic reasons, like mutations and RNA expression. Thus, these genetic features are often used to construct classification models to predict the drug response. This research focuses on the feature selection issue for the classification models. Because of the vast dimensions of the feature space for predicting drug response, the autoencoder network was first built, and a subset of inputs with the important contribution was selected. Then by using the Boruta algorithm, a further small set of features was determined for the random forest, which was used to predict drug response. Two datasets, GDSC and CCLE, were used to illustrate the efficiency of the proposed method.

[1]  Walter Kolch,et al.  Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients , 2015, Science Signaling.

[2]  R. Pal,et al.  An Ensemble Based Top Performing Approach for NCI-DREAM Drug Sensitivity Prediction Challenge , 2014, PloS one.

[3]  C. Nucera,et al.  Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. , 2010, Surgery.

[4]  Louxin Zhang,et al.  Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization , 2017, BMC Cancer.

[5]  Sergey V. Kostrov,et al.  Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios , 2013, PloS one.

[6]  Denis Bertrand,et al.  Predicting Cancer Drug Response Using a Recommender System , 2017, bioRxiv.

[7]  Fa-Yu Liu,et al.  CCR7 regulates cell migration and invasion through MAPKs in metastatic squamous cell carcinoma of head and neck. , 2014, International journal of oncology.

[8]  Tamás D. Gedeon,et al.  Data Mining of Inputs: Analysing Magnitude and Functional Measures , 1997, Int. J. Neural Syst..

[9]  U Schumacher,et al.  Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer , 2010, Oncogene.

[10]  C. Watts,et al.  Cystatin F Ensures Eosinophil Survival by Regulating Granule Biogenesis , 2016, Immunity.

[11]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[12]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[13]  Howard A. Fine,et al.  Predicting in vitro drug sensitivity using Random Forests , 2011, Bioinform..

[14]  Chun Xing Li,et al.  Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection , 2015, BMC Cancer.

[15]  Tero Aittokallio,et al.  Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization , 2016, Bioinform..

[16]  Heng Zhao,et al.  The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer. , 2014, Biochemical and biophysical research communications.

[17]  Elias Chaibub Neto,et al.  The Stream Algorithm: Computationally Efficient Ridge-Regression via Bayesian Model Averaging, and Applications to Pharmacogenomic Prediction of Cancer Cell Line Sensitivity , 2013, Pacific Symposium on Biocomputing.

[18]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[19]  Nci Dream Community A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[20]  Isidro Cortes-Ciriano,et al.  Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel , 2015, Bioinform..

[21]  Jun Cao,et al.  The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells , 2015, Medical Oncology.

[22]  Lynda Chin,et al.  MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB , 2016, Clinical Cancer Research.

[23]  Andrew H. Beck,et al.  PharmacoGx: an R package for analysis of large pharmacogenomic datasets , 2015, Bioinform..

[24]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[25]  Juho Rousu,et al.  Identification of drug candidates and repurposing opportunities through compound–target interaction networks , 2015, Expert opinion on drug discovery.

[26]  Viswanath Gunda,et al.  Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines. , 2016, Surgery.

[27]  J. C. Correa,et al.  Random forests to predict rectal toxicity following prostate cancer radiation therapy. , 2014, International journal of radiation oncology, biology, physics.

[28]  E. Seto,et al.  HDACs and HDAC Inhibitors in Cancer Development and Therapy. , 2016, Cold Spring Harbor perspectives in medicine.

[29]  In-Chul Park,et al.  Alteration of miRNA profiles by ionizing radiation in A549 human non-small cell lung cancer cells. , 2009, International journal of oncology.

[30]  Julio Saez-Rodriguez,et al.  Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.

[31]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[32]  E. Dı́az-Rodrı́guez,et al.  Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer , 2018, International journal of oncology.

[33]  Witold R. Rudnicki,et al.  Feature Selection with the Boruta Package , 2010 .

[34]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[35]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Yi-Ting Fang,et al.  Annexin A2 Silencing Induces G2 Arrest of Non-small Cell Lung Cancer Cells through p53-dependent and -independent Mechanisms* , 2012, The Journal of Biological Chemistry.

[37]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[38]  Paul S Mischel,et al.  Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.

[39]  Cheng-Yuan Liou,et al.  Modeling word perception using the Elman network , 2008, Neurocomputing.

[40]  Xiaoqi Zheng,et al.  A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia , 2016, Scientific Reports.

[41]  Diego Franco,et al.  Protein distribution of Kcnq1, Kcnh2, and Kcne3 potassium channel subunits during mouse embryonic development. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[42]  P. Steerenberg,et al.  Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. , 2010, Annals of the rheumatic diseases.

[43]  Xu Wang,et al.  Targeting the IDO1 pathway in cancer: from bench to bedside , 2018, Journal of Hematology & Oncology.

[44]  Taravat Ghafourian,et al.  Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. , 2014, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[45]  Zhi-Hua Zhou,et al.  Exploratory Under-Sampling for Class-Imbalance Learning , 2006, Sixth International Conference on Data Mining (ICDM'06).

[46]  V. Bajic,et al.  DWFS: A Wrapper Feature Selection Tool Based on a Parallel Genetic Algorithm , 2015, PloS one.

[47]  Zhuowen Tu,et al.  Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.

[48]  Jun Wang,et al.  Predicting Anticancer Drug Responses Using a Dual-Layer Integrated Cell Line-Drug Network Model , 2015, PLoS Comput. Biol..

[49]  Yuri Nikolsky,et al.  Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib , 2015, PloS one.

[50]  Krister Wennerberg,et al.  Integrative and Personalized QSAR Analysis in Cancer by Kernelized Bayesian Matrix Factorization , 2014, J. Chem. Inf. Model..

[51]  Jesper Tegnér,et al.  Consistent Feature Selection for Pattern Recognition in Polynomial Time , 2007, J. Mach. Learn. Res..

[52]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[53]  R. Geha,et al.  2. Update on primary immunodeficiency diseases. , 2006, The Journal of allergy and clinical immunology.

[54]  Vedrana Milinkovic,et al.  Identification of genes associated with non-small-cell lung cancer promotion and progression. , 2010, Lung cancer.

[55]  Yanwen Chen,et al.  Drug Intervention Response Predictions with Paradigm (DIRPP) Identifies Drug Resistant Cancer Cell Lines and Pathway Mechanisms of Resistance , 2014, Pacific Symposium on Biocomputing.